Ex vivo expansion of natural killer cells from human peripheral blood mononuclear cells co-stimulated with anti-CD3 and anti-CD52 monoclonal antibodies

Cytotherapy

Volumn 18, Issue 1, 2016, Pages 80-90

  Masuyama, Jun ichi ^a,b   Murakami, Takashi ^c   Iwamoto, Sanju ^d   Fujita, Sanehiko ^a  

^a New City Osaki Clinic   (Japan)

^b JICHI MEDICAL UNIVERSITY   (Japan)

^c TAKASAKI UNIVERSITY OF HEALTH AND WELFARE   (Japan)

^d SHOWA UNIVERSITY   (Japan)

Author keywords

CD52; Co stimulation; Immunotherapy; NK cell expansion

Indexed keywords

CD3 ANTIGEN; CD52 ANTIGEN; CELL SURFACE RECEPTOR; GAMMA INTERFERON; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; MONOCLONAL ANTIBODY; TUMOR ANTIGEN; TUMOR MARKER;

ANIMAL; BIOSYNTHESIS; CASE REPORT; CD4+ T LYMPHOCYTE; CELL PROLIFERATION; CELL SEPARATION; CYTOLOGY; CYTOTOXICITY; DRUG EFFECTS; HUMAN; IMMUNOLOGY; K562 CELL LINE; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MIDDLE AGED; MOUSE; NATURAL KILLER CELL; PHENOTYPE;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD; ANTIGENS, CD3; ANTIGENS, NEOPLASM; BIOMARKERS, TUMOR; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL SEPARATION; CYTOTOXICITY, IMMUNOLOGIC; GLYCOPROTEINS; HUMANS; INTERFERON-GAMMA; K562 CELLS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; MALE; MICE; MIDDLE AGED; PHENOTYPE; RECEPTORS, CELL SURFACE;

EID: 84955354687     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2015.09.011     Document Type: Article

References (42)

1. Trinchieli G. Biology of natural killer cells. Adv Immunol 1989, 47:187-376. pmid:2683611.
2. Lanier L.L. Natural killer cell receptor signaling. Curr Opin Immunol 2003, 15:308-314. pmid:12787756.
3. Long E.O., Kim H.S., Liu D., Peterson M.E., Rajagopalan S. Controlling natural killer cell responses: integration of signals for activation and inhibition. Annu Rev Immunol 2013, 31:227-258. pmid:23516982.
4. Campbell K.S., Purdy A.K. Structure/function of human killer cell immunoglobulin-like receptors: lessons from polymorphisms, evolution, crystal structures and mutations. Immunology 2011, 132:315-325. pmid:21214544.
5. Morreta A., Bottino C., Vitale M., Pende D., Cantoni C., Mingari M.C., et al. Activating receptors and coreceptors involved in human natural killer cell-mediated cytolysis. Annu Rev Immunol 2001, 19:197-223. pmid:11244035.
6. Kärre K., Ljunggren H.G., Piontek G., Kiessling R. Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defense strategy. Nature 1986, 319:675-678. pmid:3951539.
7. Kärre K. NK cells, MHC class I molecules and the missing self. Scand J Immunol 2002, 55:221-228. pmid:12787756.
8. Sutlu T., Alici E. Natural killer cell-based immunotherapy in cancer: current insights and future prospects. J Intern Med 2009, 266:154-181. pmid:19614820.
9. Bachanova V., Miller J.S. NK cells in therapy of cancer. Crit Rev Oncog 2014, 19:133-141. pmid:24941379.
10. Cheng M., Chen Y., Xiao W., Sun R., Tian Z. NK cell-based immunotherapy for malignant diseases. Cell Mol Immunol 2013, 10:230-252. pmid:23604045.
11. Childs R.W., Berg M. Bringing natural killer cells to the clinic: ex vivo manipulation. Hematology Am Soc Hematol Educ Program 2013, 2013:234-246. pmid:24319186.
12. Parkhurst M.R., Riley J.P., Dudley M.E., Rosenberg S.A. Adoptive transfer of autologous natural killer cells leads to high levels of circulating natural killer cells but does not mediate tumor regression. Clin Cancer Res 2011, 17:6287-6297. pmid:21844012.
13. Berg M., Lundqvist A., McCoy P., Samsel L., Fan Y., Tawab A., et al. Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells. Cytotherapy 2009, 11:341-355. pmid:19308771.
14. Fujisaki H., Kakuda H., Shimasaki N., Imai C., Ma J., Lockey T., et al. Expansion of highly cytotoxic human natural killer cells for cancer cell therapy. Cancer Res 2009, 69:4010-4017. pmid:19383914.
15. Denman C.J., Senyukov V.V., Somanchi S.S., Phatarpekar P.V., Kopp L.M., Johnson J.L., et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 2012, 7:e30264. pmid:22279576.
16. Yanagisawa S., Kadouchi I., Yokomori K., Hirose M., Hakozaki M., Hojo H., et al. Identification and metastatic potential of tumor-initiating cells in malignant rhabdoid tumor of the kidney. Clin Cancer Res 2009, 5:3014-3022. pmid:19383826.
17. Tezuka Y., Endo S., Matsui A., Sato A., Saito K., Semba K., et al. Potential anti-tumor effect of IFN-λ2 (IL-28A) against human lung cancer cells. Lung Cancer 2012, 78:185-192. pmid:23021208.
18. + dendritic cells evoking Th1 and Th17 responses. J Immunol 2007, 179:1449-1457. pmid:17641010.
19. Inoue Y., Kiryu S., Izawa K., Watanabe M., Tojo A., Ohtomo K. Comparison of subcutaneous and intraperitoneal injection of D-luciferin for in vivo bioluminescence imaging. Eur J Nucl Med Mol Imaging 2009, 36:771-779. pmid:19096841.
20. Sato A., Ohtsuki M., Hata M., Kobayashi E., Murakami T. Antitumor activity of interferon (IFN)-lambda in murine tumor models. J Immunol 2006, 176:7686-7694. pmid:16751416.
21. Murakami T., Sato A., Chun N.A.L., Hara M., Naito Y., Kobayashi Y., et al. Transcriptional modulation using HDACi depsipeptide promotes immune cell-mediated tumor destruction of murine B16 melanoma. J Invest Dermatol 2008, 128:1506-1516. pmid:18185535.
22. + regulatory T cells. J Immunol 2002, 169:3710-3716. pmid:12244164.
23. + regulatory T cells. Clin Immunol 2006, 120:247-259. pmid:16797237.
24. Hale G., Xia M.Q., Tighe H.P., Dyer M.J., Waldmann H. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990, 35:118-127. pmid:2165283.
25. Masuyama J., Yoshio T., Suzuki K., Kitagawa S., Iwamoto M., Kamimura T., et al. Characterization of the 4C8 antigen involved in transendothelial migration of CD26hi T cells after tight adhesion to human umbilical vein endothelial cell monolayers. J Exp Med 1999, 189:979-990. pmid:10075981.
26. Greenfield E.A., Nguyen K.A., Kuchroo V.K. CD28/B7 costimulation: a review. Crit Rev Immunol 1998, 18:389-418. pmid:9784967.
27. Wing M.G., Moreau T., Greenwood J., Smith R.M., Hale G., Isaacs J., et al. Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD16 (FcgammaRIII) and CD11a/CD18 (LFA-1) on NK cells. J Clin Invest 1996, 98:2819-2826. pmid:8981930.
28. Takada M., Terunuma H., Deng X., Dewan M.Z., Saji S., Kuroi K., et al. Refractory lung metastasis from breast cancer treated with multidisciplinary therapy including an immunological approach. Breast Cancer 2011, 18:64-67. pmid:20354831.
29. Hale G. Synthetic peptide mimotope of the CAMPATH-1 (CD52) antigen, a small glycosylphosphatidylinositol-anchored glycoprotein. Immunotechnology 1995, 1:175-187. pmid:9373346.
30. Warner J.L., Arnason J.E. Alemtuzumab use in relapsed and refractory chronic lymphocytic leukemia: a history and discussion of future rational use. Ther Adv Hematol 2012, 3:375-389. pmid:23606939.
31. Zinzani P.L., Corradini P., Gallamini A., Grossi A., Lazzarino M., Marchetti M., et al. Overview of alemtuzumab therapy for the treatment of T-cell lymphomas. Leuk Lymphoma 2012, 53:789-795. pmid:21980956.
32. Coles A.J., Twyman C.L., Arnold D.L., Cohen J.A., Confavreux C., Fox E.J., et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomized controlled phase 3 trial. Lancet 2012, 380:1829-1839. pmid:23122650.
33. Coles A.J. Alemtuzumab therapy for multiple sclerosis. Neurother 2013, 10:29-33. pmid:23184314.
34. Rowan W.C., Hale G., Tite J.P., Brett S.J. Cross-linking of the CAMPATH-1 antigen (CD52) triggers activation of normal human T lymphocytes. Int Immunol 1995, 7:69-77. pmid:7718516.
35. Levitsky J., Leventhal J.R., Miller J., Huang X., Chen L., Chandrasekaran D., et al. Favorable effects of alemtuzumab on allospecific regulatory T-cell generation. Hum Immunol 2012, 73:141-149. pmid:22154724.
36. Bandala-Sanchez E., Zhang Y., Reinwald S., Dromey J.A., Lee B.H., Qian J., et al. T cell regulation mediated by interaction of soluble CD52 with the inhibitory receptor Siglec-10. Nat Immunol 2013, 14:741-748. pmid:23685786.
37. Moreau T., Coles A., Wing M., Isaacs J., Hale G., Waldmann H., et al. Transient increase in symptoms associated with cytokine release in patients with multiple sclerosis. Brain 1996, 119:225-237. pmid:8624684.
38. Betters D.M., Smith A.L., Berg M., Lundqvist A., Childs R.W. In vitro expanded natural killer (NK) cells are more susceptible to Fas-mediated apoptosis compared to fresh and overnight IL-2 activated NK cells. Cancer Res 2010, 70(8 Suppl.). Abstract 1271.
39. Miller J.S. Therapeutic applications: natural killer cells in the clinic. Hematology Am Soc Hematol Educ Program 2013, 2013:247-253. pmid:24319187.
40. + T regulatory cells suppress NK cell-mediated immunotherapy of cancer. J Immunol 2006, 176:1582-1587. pmid:16424187.
41. + and NK lymphocytes in the direct cell-to-cell interaction. Clin Immunol 2004, 112:258-267. pmid:15308119.
42. Zervos E.E., Osborne D., Boe B.A., Luzardo G., Goldin S.B., Rosemurgy A.S. Prognostic significance of new onset ascites in patients with pancreatic cancer. World J Surg Oncol 2006, 4:16. pmid:16569225.